Advantages of multi-arm non-randomised sequentially allocated cohort designs for Phase II oncology trials

Background Efficient trial designs are required to prioritise promising drugs within Phase II trials. Adaptive designs are examples of such designs, but their efficiency is reduced if there is a delay in assessing patient responses to treatment. Methods Motivated by the WIRE trial in renal cell carc...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	British journal of cancer Jg. 126; H. 2; S. 204 - 210
Hauptverfasser:	Mossop, Helen, Grayling, Michael J., Gallagher, Ferdia A., Welsh, Sarah J., Stewart, Grant D., Wason, James M. S.
Format:	Journal Article
Sprache:	Englisch
Veröffentlicht:	London Nature Publishing Group UK 01.02.2022 Nature Publishing Group
Schlagworte:	692/308/2779/109/2425 692/308/2779/777 Adaptive Clinical Trials as Topic - methods Biomedical and Life Sciences Biomedicine Cancer Research Cancer therapies Clinical trials Clinical Trials, Phase II as Topic - methods Cohort Studies Computer Simulation - standards Drug Resistance Efficiency Epidemiology Humans Hypotheses Kidney cancer Medical Oncology - methods Molecular Medicine Neoplasms - drug therapy Neoplasms - pathology Non-Randomized Controlled Trials as Topic - methods Oncology Patients Recruitment Renal cell carcinoma Research Design - standards Response rates Sample Size Simulation Surgery Treatment Outcome
ISSN:	0007-0920, 1532-1827, 1532-1827
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Schreiben Sie den ersten Kommentar!